Contents

Part I Design Considerations

1 The Need for and the Future of Adaptive Designs in Clinical Development ................................................................. 3
   Christy Chuang-Stein and Frank Bretz

2 Regulatory Guidance Documents on Adaptive Designs: An Industry Perspective ................................................................. 25
   José Pinheiro

3 A Commentary on the U.S. FDA Adaptive Design Draft Guidance and EMA Reflection Paper from a Regulatory Perspective and Regulatory Experiences .................................................. 43
   Sue-Jane Wang

4 Considerations and Optimization of Adaptive Trial Design in Clinical Development Programs ................................................. 69
   Michael Krams and Vladimir Dragalin

5 Optimal Cost-Effective Go–No Go Decisions in Clinical Development .......................................................... 91
   Cong Chen, Robert A. Beckman, and Linda Z. Sun

6 Timing and Frequency of Interim Analyses in Confirmatory Trials .............................................................. 115
   Keaven M. Anderson

7 Approaches for Optimal Dose Selection for Adaptive Design Trials .............................................................. 125
   David Lawrence and Frank Bretz

8 A Review of Available Software and Capabilities for Adaptive Designs ............................................................. 139
   Yevgen Tymofyeyev
9 Randomization Challenges in Adaptive Design Studies...................... 157
Olga M. Kuznetsova

10 Response-Adaptive Randomization for Clinical Trials ...................... 183
Lanju Zhang and William F. Rosenberger

Part II Trial Implementation Considerations

11 Implementing Adaptive Designs: Operational Considerations,
Putting It All Together................................................................. 203
Olga Marchenko and Christy Nolan

12 Implementation Issues in Adaptive Design Trials.......................... 225
Linda Danielson, Jerome Carlier, Tomasz Burzykowski,
and Marc Buyse

13 Implementing Adaptive Designs: Using Technology
to Protect Trial Integrity, Reduce Operational Bias,
and Build Regulatory Trust .......................................................... 241
Judith Quinlan and Michael Krams

14 Considerations for Interim Analyses in Adaptive Trials,
and Perspectives on the Use of DMCs............................................ 259
Paul Gallo, David DeMets, and Lisa LaVange

15 Approaches for Clinical Supply Modelling and Simulation .......... 273
Nitin R. Patel, Suresh Ankolekar, and Pralay Senchaudhuri

16 Approaches for Patient Recruitment Modeling and Simulation ...... 299
Weili He and Xiting Cao

Part III Case Studies

17 A Case Study for Adaptive Trial Design Consideration
and Implementation........................................................................ 321
Vladimir Dragalin and Michael Krams

18 Case Study: Design Considerations for a Phase Ib
Randomized, Placebo-Controlled, 4-Period Crossover
Adaptive Dose-Finding Clinical Trial ............................................. 341
James A. Bolognese and Yevgen Tymofyeyev

19 Continual Reassessment Method for a First-in-Human Trial:
From Design to Trial Implementation ............................................ 357
Inna Perevozskaya, Lixin Han, and Kristen Pierce
20  Practical Considerations for a Two-Stage Confirmatory
Adaptive Clinical Trial Design and Its Implementation:
ADVENT Trial ................................................................. 383
Pravin R. Chaturvedi, Zoran Antonijevic, and Cyrus Mehta

Index.................................................................................. 413
Practical Considerations for Adaptive Trial Design and Implementation
He, W.; Pinheiro, J.; Kuznetsova, O.M. (Eds.)
2014, XX, 416 p. 66 illus., 41 illus. in color., Hardcover
ISBN: 978-1-4939-1099-1